AstraZeneca has opened a new global strategic research and development (R&D) centre, in Kendall Square, Cambridge, Massachusetts, USA.
The new state-of-the-art facility builds on the company’s existing presence in Cambridge and Boston and places its scientists at the heart of one of the world’s most innovative life sciences ecosystems.
Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kendall Square will be home to nearly 2,000 world-class researchers and scientists who will accelerate the company’s oncology, cell therapy, chronic disease and rare disease pipeline to deliver transformative medicines of the future.
The 570,000 square foot, 18-storey site at 290 Binney Street is designed to enhance collaboration and was built with the highest standards of sustainable design to minimise our impact on the planet.
The R&D centre includes ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI.
Leading experts will deliver novel treatments from our pipeline to treat people struggling to live with diseases such as COPD, obesity and metabolic disease, breast cancer and rare diseases, while focusing on the next wave of future innovation in areas like cell therapy and biologics to fuel AstraZeneca’s growth beyond 2030.
The opening of these laboratories marks a significant milestone in AstraZeneca’s more than 75-year history in Massachusetts. As part of its broader US investment of US $50 billion, AstraZeneca is investing more than US $1 billion in Massachusetts, USA, which will directly expand its workforce in the state by over 50 per cent in the coming years and contribute billions in additional economic value and jobs across the Commonwealth.
This new site adds to AstraZeneca’s existing R&D presence in more than 40 countries across the globe, including its other US-based global strategic research centre in Gaithersburg, Maryland.
In the US, The AstraZeneca R&D Center Kendall Square joins the Company’s coast-to-coast footprint of 24 R&D, manufacturing, commercial and corporate sites. AstraZeneca’s US workforce exceeds more than 25,000 people and supports nearly 100,000 jobs overall across the country.
